1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

MyoKardia's Mavacamten 'Impressive' In Hypertrophic Cardiomyopathy

Launch Planning Underway For The Biotech's Lead Candidate

 
• By John Davis

MyoKardia is building up its organization to prepare for commercialization of mavacamten, a potential first-in-class agent for obstructive hypertrophic cardiomyopathy.  

Cardiomyopathy
• Source: Shutterstock

Updated results from the Phase III EXPLORER-HCM trial have continued to portray the clinical benefits of MyoKardia, Inc.’s mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (HCM). With a US new drug application expected to be submitted in the first quarter of 2021, the Brisbane, CA-based company has sketched out commercialization plans for its lead first-in-class therapeutic candidate. 

Mavacamten has the potential to be the first therapeutic candidate to target excessive contractility and impaired relaxation associated with obstructive HCM, and the company plans to become the global leader in HCM, going beyond therapy to include diagnosis and patient care plans

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.